REMEGEN's stock price surged 5.17% during intraday trading on Wednesday, reflecting strong positive momentum in the market.

The significant rise follows the company's announcement that its core ADC drug, disitamab vedotin (RC48, Aidixin), received formal approval from China's National Medical Products Administration for a new indication. The drug is now approved for combination therapy with toripalimab for the first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma, marking it as the world's first HER2-ADC therapy approved for this first-line use and representing a major expansion from later-line treatment.

Additionally, the company reported robust financial performance with full-year revenue surging 89.36% year-over-year and achieving a net profit of RMB 710 million, completing a turnaround from loss to profitability. The stock has also attracted significant institutional interest, with 48 mutual funds holding positions and 10 institutions issuing buy ratings over the past 90 days.